A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
medinfo@incyte.com1.855.463.3463
eumedinfo@incyte.com+800 00027423
La Jolla, California 92037, United States
Richmond, Virginia 23298, United States
Heidelberg, Victoria 03084, Australia
LINZ CET, A-4020, Austria
Vienna, 01090, Austria
Nantes, 44903, France
Toulouse, 31059, France
Alessandria, 15121, Italy
Milan, 20162, Italy
Aichi-ken, 446-8602, Japan
Isehara Kanagawa, 259-1193, Japan
Kumamoto Kumamoto, 860-0008, Japan
Okayama Okayama, 700-0914, Japan
Sapporo Hokkaido, 060-0814, Japan
Tokyo, 113-0021, Japan
L'Hospitalet de Llobregat, 08906, Spain
Las Palmas de Gran Canaria, 35010, Spain